title: Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement.
abstract: Sunitinib malate, an oral multitargeted tyrosine kinase inhibitor (TKI), has been approved for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors. It is supposed that this targeted approach improves antitumor activity with less toxicity than traditional chemotherapy. However, unanticipated cardiotoxicity related to TKIs has been reported. Less well described are the treatment and prognosis of patients with sunitinib-related cardiogenic shock. Here, we report a successfully treated case. In contrast to previous case reports, the shock status did not allow for standard heart failure treatment with angiotensin-converting enzyme inhibitor or beta-blocker. We used intra-aortic balloon counterpulsation, and the patient survived. Twenty-four days after onset, the patient's left ventricular ejection fraction had improved from 20% to 48%. To the best of our knowledge, this is the first case report of severe heart failure after sunitinib treatment in Taiwan. As the clinical application of TKIs expands, cardiologists and oncologists should be alert to the possible adverse cardiovascular effects and be ready to institute prompt treatment.
authors.affiliation: Department of Cardiovascular Medicine, Far-Eastern Memorial Hospital, Banqiao, Taiwan, R.O.C.
authors.forename: Ching-Fen
authors.initials: CF
authors.lastname: Wu
authors.forename: Wen-Po
authors.initials: WP
authors.lastname: Chuang
authors.forename: Ai-Hsien
authors.initials: AH
authors.lastname: Li
authors.forename: Chi-Huang
authors.initials: CH
authors.lastname: Hsiao
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004562:Electrocardiography; D005260:Female; D005682:Gadolinium; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007089:Image Enhancement; D007211:Indoles / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D005682:Gadolinium; D000077210:Sunitinib